Condition
Advanced Solid Tumour
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Recruiting4
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07390383Phase 2RecruitingPrimary
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
NCT07111546Phase 2RecruitingPrimary
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07331155Phase 2RecruitingPrimary
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
NCT06783647Phase 2RecruitingPrimary
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT05109650Phase 1TerminatedPrimary
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
Showing all 5 trials